Clinical Trials Logo

Follicular Lymphoma clinical trials

View clinical trials related to Follicular Lymphoma.

Filter by:

NCT ID: NCT05389293 Recruiting - Lymphoma Clinical Trials

A Study of Mosunetuzumab in People With Follicular Lymphoma

Start date: May 27, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.

NCT ID: NCT05365659 Recruiting - Clinical trials for Mantle Cell Lymphoma

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

Start date: September 5, 2023
Phase: Phase 1
Study type: Interventional

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma (NHL).

NCT ID: NCT05326308 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma

ARIADNE
Start date: April 26, 2022
Phase:
Study type: Observational

The objective of this NIS is to evaluate medical resource utilization, where data is rare in all cohorts, patient's QoL and effectiveness of zanubrutinib treatment in adult patients with WM, CLL, MZL and FL in a real-world setting.

NCT ID: NCT05294731 Recruiting - Clinical trials for Mantle Cell Lymphoma

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Start date: March 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts

NCT ID: NCT05284825 Recruiting - Follicular Lymphoma Clinical Trials

A Phase II Trial of Intermediate Radiation Dose For Lymphoma

Start date: February 28, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the optimal radiation dose fractionation regimen for low grade follicular lymphoma. It is hypothesized that the complete response rate with the use of 12 Gy in 6 daily fractions is 80% (10% total width of the confidence interval) at 3 months. This phase II study will evaluate whether an intermediate dose for follicular lymphoma is associated with excellent response rates while minimizing acute and late toxicity.

NCT ID: NCT05281809 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

Start date: April 19, 2022
Phase: Phase 2
Study type: Interventional

This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.

NCT ID: NCT05255354 Recruiting - Clinical trials for Mantle Cell Lymphoma

Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

Start date: June 1, 2022
Phase:
Study type: Observational

In this study, invesigators propose to analyze 150 DLBCL patients, 50 MCL patients, and 100 FL patients to determine the clinical utility of ctDNA- as well as circulating tumor cell (CTC)-based MRD assessment in CAR therapy patients. The project detailed in this protocol will utilize the clonoSEQ platform as specific quantification of residual DLBCL/FL/MCL and correlate its results with radiologic assessment of disease and clinical outcomes. Invesitgators predict there will be a strong correlation between ctDNA and PET/CT and dynamic changes in ctDNA will precede radiologic evidence of disease recurrence in patients following CAR therapy.

NCT ID: NCT05058404 Recruiting - Follicular Lymphoma Clinical Trials

Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Start date: December 1, 2021
Phase: Phase 3
Study type: Interventional

FIL_FOLL19 is an open-label, multicenter, randomized phase III trial. The sponsor of this clinical trial is Fondazione Italiana Linfomi (FIL). The Primary Objective of the study is to demonstrate that, in patients with newly diagnosed, advanced stage Follicular Lymphoma (FL) with high tumor burden according to the Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria, a treatment strategy that reduces the number of chemotherapy cycles in case of early response to immunochemotherapy is not inferior compared to standard therapy at full dose in terms of Progression-Free Survival (PFS).

NCT ID: NCT05020392 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma

Start date: September 14, 2021
Phase: Phase 3
Study type: Interventional

This is a single-center, open-label and pragmatic clinical trial to evaluate the primary efficacy and safety of anti-CD19 chimeric antigen receptor (CAR)-modified T cells (CART-CD19) with concurrent BTK inhibitor in patients with relapsed or refractory B cell lymphoma

NCT ID: NCT05006716 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Start date: September 13, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)